Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L04AB04

Humira(adalimumab)

Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Uveitis;Colitis, Ulcerative;Psoriasis;Arthritis, Psoriatic;Crohn Disease;Arthritis, Rheumatoid

Marketing Authorisation Holder: AbbVie Deutschland GmbH & Co. KG

EMA Authorisation: 08/09/2003

INN: adalimumab

Indication

Please refer to the product information document.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Humira — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.